title: American Association for Cancer Research--94th Annual Meeting.  New compounds. 11-14 July 2003, Washington, DC, USA.
authors.affiliation: Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, UK. janie.mackay@current-drugs.com
authors.forename: Janie
authors.initials: J
authors.lastname: Mackay
authors.forename: Laura
authors.initials: L
authors.lastname: Williams
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D050796:STAT3 Transcription Factor; D015534:Trans-Activators / Q000037:antagonists & inhibitors; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D015534:Trans-Activators; D040262:Receptors, Vascular Endothelial Growth Factor; D040301:Vascular Endothelial Growth Factor Receptor-2; D019061:src-Family Kinases; D018844:Cyclin-Dependent Kinases